Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott investigation

This article was originally published in The Gray Sheet

Executive Summary

The U.S. Attorney's Office in Massachusetts subpoenaed Abbott Laboratories in June to retrieve information on the firm's sales and marketing of its biliary stent product (Xpert), Abbott disclosed in a July 25 filing with U.S. Securities and Exchange Commission. FDA has publicly scolded companies including Abbott, Boston Scientific and C.R. Bard for marketing the stents, intended for the bile duct, for use to treat peripheral vascular diseases (1"The Gray Sheet" March 19, 2007, p. 10). The Department of Justice is now investigating companies to determine if the marketing activities might have risen to the level of violating civil or criminal laws including the Federal False Claims Act, the Food and Drug Cosmetic Act and the Anti-Kickback Statute
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT026394

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel